Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus ORASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus ORASONE.
DEXASPORIN vs ORASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
None Documented
None Documented
Clinical Note
moderateDiflorasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin."
Clinical Note
moderateDiflorasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin."
Clinical Note
moderateDiflorasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin."
Clinical Note
moderateDiflorasone + Trovafloxacin
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Trovafloxacin."